Evidence map›Paper›PMID 32397786›Full record

ArticlemAbs

Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoires.

Samuel Schmitz, Cinque Soto, James E Crowe, Jens Meiler

Open access · goldAbstract readComparative Study
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Toward Drug-Like Multispecific Antibodies by Design.International journal of molecular sciences · 2020
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Samuel SchmitzDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-5314-6095
Cinque SotoDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-3997-6217
James E CroweDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-0049-1079
Jens MeilerDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0001-8945-193X
Vanderbilt University Medical Center · USLeipzig University of Applied Sciences · DEVanderbilt University · US

Funding

Structure based design of antibodies and vaccinesU19AI117905 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SCHIEF, WILLIAM R. · 2015 to 2019
$12.0M
Structure based design of trimer interface epitope focused universal influenza vaccinesU01AI150739 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2020 to 2024
$6.1M
Epitope-Based Design and Modified RNA Platform for Bivalent Marburgvirus VaccineR01AI141661 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, CROWE, JAMES E · 2019 to 2023
$3.9M
NIAID NIH HHS R01 AI141661NIAID NIH HHS U01 AI150739NIAID NIH HHS U19 AI117905
6 · The paper itself

Abstract

The antibody (Ab) germline gene rearrangement of variable (V), diversity (D), and joining (J) gene segments, as well as somatic hypermutation, give rise to the human Ab variable gene sequence repertoire. It is common to characterize single nucleotide frequencies of the variable region by alignment to species-specific wildtype germline genes. The increasing application of next-generation sequencing to immune repertoire studies has led to the compilation of increasing large adaptive immunome receptor repertoire datasets. We have developed a method that maps the sequence of a target Ab onto an immunome dataset of 326 million human Ab sequences. For this purpose, we created a position- and gene-specific scoring matrix (PGSSM) and its corresponding antibody similarity score. We characterized our PGSSM score and found that it strongly correlated with the phylogenetic distance of 181,355 Ab sequences from GenBank across 20 species. The most likely human nucleotide back-translation was obtained given only PGSSMs and the amino acid sequence of an Ab achieving a nucleotide sequence recovery of 95.9% and 97.2% for human heavy and light chains, respectively. In conclusion, the scoring of our back-translation is a valuable estimate for the similarity of an Ab sequence to the natural human repertoire. As expected, Ab therapeutic molecules developed from a human source showed a higher similarity to the repertoire than engineered Abs. Thus, the PGSSM metric introduced here can be used to engineer human-like Ab therapeutics.

Indexed as

AlgorithmsAmino Acid SequenceAnimalsAntibody DiversityBase SequenceBiological ProductsGene RearrangementGenes, ImmunoglobulinGerm CellsHigh-Throughput Nucleotide SequencingHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionPolymorphism, Single NucleotideSpecies SpecificityBiological ProductsImmunoglobulin Heavy ChainsImmunoglobulin Variable Regionantibody diversitybiostatisticsgene rearrangementhigh-throughput nucleotide sequencingimmunoglobulin variable regionsequence analysisSingle nucleotide polymorphism

Identifiers

PMID32397786
PMCPMC8648325
OpenAlexW3024610894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.